0001477932-24-000494.txt : 20240201 0001477932-24-000494.hdr.sgml : 20240201 20240201083025 ACCESSION NUMBER: 0001477932-24-000494 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240131 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Innovation Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001355250 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 300565645 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37357 FILM NUMBER: 24585135 BUSINESS ADDRESS: STREET 1: 301 EDGEWATER PLACE STREET 2: SUITE 100 CITY: WAKEFIELD STATE: MA ZIP: 01880 BUSINESS PHONE: 978-921-4125 MAIL ADDRESS: STREET 1: 301 EDGEWATER PLACE STREET 2: SUITE 100 CITY: WAKEFIELD STATE: MA ZIP: 01880 FORMER COMPANY: FORMER CONFORMED NAME: Cellceutix CORP DATE OF NAME CHANGE: 20080515 FORMER COMPANY: FORMER CONFORMED NAME: EconoShare, Inc. DATE OF NAME CHANGE: 20060306 8-K 1 ipix_8k.htm FORM 8-K ipix_8k.htm

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 31, 2024

 

INNOVATION PHARMACEUTICALS INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

 

001-37357

 

30-0565645

(State or Other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 

301 Edgewater Place - Suite 100

Wakefield, Massachusetts

 

01880

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (978) 921-4125

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Exchange Act: none

 

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 31, 2024, Barry Schechter and Zorik Spektor each resigned from the Board of Directors of Innovation Pharmaceuticals Inc. (the “Company”), effective immediately. Their decisions to resign were not the result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices.

 

Item 8.01 Other Events.

 

As previously disclosed, on January 22, 2020, the Company filed a complaint against Cummings Properties, LLC (“Cummings”) in the Superior Court of the Commonwealth of Massachusetts (C.A. No. 20-77CV00101), seeking, among other things, declaratory relief that the lease relating to the Company’s prior principal executive offices terminated in September 2018 rather than automatically extending for an additional five years. On August 29, 2023, the trial for this case commenced, and on January 18, 2024, the Court ruled in favor of Cummings, finding that Cummings is entitled to recover liquidated damages in the amount of $810,251.36, minus the Company’s $77,600 security deposit, plus eighteen percent per annum interest owing since January 17, 2020. The Company intends to appeal the decision.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 INNOVATION PHARMACEUTICALS INC.
    
Dated: February 1, 2024By:/s/ Leo Ehrlich

 

Name:

Leo Ehrlich 
 Title: Chief Executive Officer 

 

 

3

 

 

 EX-101.SCH 2 ipix-20240131.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ipix-20240131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 4 ipix-20240131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 5 ipix-20240131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 6 ipix-20240131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Jan. 31, 2024
Cover [Abstract]  
Entity Registrant Name INNOVATION PHARMACEUTICALS INC.
Entity Central Index Key 0001355250
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jan. 31, 2024
Entity File Number 001-37357
Entity Incorporation State Country Code NV
Entity Tax Identification Number 30-0565645
Entity Address Address Line 1 301 Edgewater Place
Entity Address Address Line 2 Suite 100
Entity Address City Or Town Wakefield
Entity Address State Or Province MA
Entity Address Postal Zip Code 01880
City Area Code 978
Local Phone Number 921-4125
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 20 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://ipix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ipix-20240131.xsd ipix-20240131_cal.xml ipix-20240131_def.xml ipix-20240131_lab.xml ipix-20240131_pre.xml ipix_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ipix_8k.htm": { "nsprefix": "ipix", "nsuri": "http://ipix.com/20240131", "dts": { "schema": { "local": [ "ipix-20240131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ipix-20240131_cal.xml" ] }, "definitionLink": { "local": [ "ipix-20240131_def.xml" ] }, "labelLink": { "local": [ "ipix-20240131_lab.xml" ] }, "presentationLink": { "local": [ "ipix-20240131_pre.xml" ] }, "inline": { "local": [ "ipix_8k.htm" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 21, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "report": { "R1": { "role": "http://ipix.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-31to2024-01-31", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ipix_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-31to2024-01-31", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ipix_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ipix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001477932-24-000494-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-24-000494-xbrl.zip M4$L#!!0 ( ,M#05C+_]_VB 0 (,6 1 :7!I>"TR,#(T,#$S,2YX M0Q P3(I( S+;(K:)JVB20YB\F*]#WGOG5)9OKQL W1CDK%!)\Y@3=P$.5$+!E?SYQ8N5@1 MQARD-.9+' I.9\Z1*N?C[8\_3']RW;?[^3-Z%"3>4J[1@Z18TR7:,[U!1O0% M*TVEZZ;HOQ,[$S3T1M[@C_SW>ZR );CE@##()8^@#XD5(D:SI0Z&_B#PAX/A M[SGH5:ST'DN*L"0;IBG1L<0A6E+%UAR!XR@):(+N?B;H<8/E%D>2;C$W0:&[ MG?9R70\B.DJVWFCT"_D5&3/HR7WY]!7=QXIQJA1Z%6%L7%&_H2=./'07AFAN M& K-J:)R1Y>I.D4V8 1!AKF:',*9L]$ZFOC^?K_W#@L9>D*N(9+!R'][9OQ? M)T5*NFJ$WO@@S8 DEA**=5K@9R MX+]]>7ZUK>+DO0+M4 :GE":&B M'\2^$1O.P+3B,"B;,LW68,J*JJ8HJX\8!!4@C[??\ 805#*2$P1OP1'&! MG[7.UXV,YG%1^:@C=LB19N,1L;73&CYE2%T^6CX+N7VD*QR'X$+,_XMQR%;, M?+(TI.8PJ0!*8HWEFNH7O*4JPH1>, 8C&$TQYT+;H\-L81]%C*^$W:"I^3PF MIE)?(4/(+/Z:/YVKM#/E0< QZ2 &PR=9)CI2)4NZ8IQ9.P/S%R"W.!==9!E3 M_Q1:UA##&?@GO[5K.)T4$*W?YFA(F2FDB45P2.*P(ZGPIH&3_I1EJ9RY;+K, MZ0K9J30QG39S%-M&H9DA]K>-/=!,,MVL-O] @!YT3 8QRB],)9O_TYRDAC,5 MF$6PJHVH*\0BI$3^;=)=.[>3*^2R(U7.!8G9NQG/-3VXPA(N6 M=U#+U+\N'A2A=?,@XW7UH/XBTM)V1C!&/[0W5W]!J;.I+E&RC6G,40_KU6M] M._-E3K[KZ4!Q6VEE.X.;17N++:XP;8I=9KXD1%/TL>FTX.8:3_IYT<^%IG=4 MJ_SG>+OJ60%[S4[G'5P B7;I(0KA_:R%/'Z&?;M$A%)6M'PJE%Q5EIJ'7UMW MRJQW\Z%#.C+&53U1?L2V:HJ"D"Q[CH+B]=_*:@8WB_86&U]5%VV>/6=\&FI5 MZ.AIO_R [&O?ZKAV%);?HTV.?(MI]ZI'V8M_;+2K>X:WJQZ9AY=F]\*7GZ=) M\C,U_3SH7OI:#SI6O^99WK?O>D5=>N%?$;3]GV/5_M1/]-W^#U!+ P04 M" #+0T%8=/^F>=D! "+ P %0 &EP:7@M,C R-# Q,S%?8V%L+GAM;(U3 M38^;,!"]5^I_F-)#6ZGF*WMH4-A5/O80*=M#LJWVZC638-78R#:!_/O:L-"- MVDK+ 6'FO7GO#)&$< $JF"BY/>= 80@WC/ !CJ2RH4!+S MX((FN+M]_V[Q@9"GU7X'&\6:"J6%M49JL8"6VQ)\Z8$:BYJ0%_3/02>#-)R% M\;?I_8H:QU*RY[AB,E4VKA^H(S#?N:?&:10G41JG-Q/HH(ZVI1J!:E9RB\PV MF@HHT/"3!&</L&H,EV@,')1HO!7S%;:2A; 4 O:>86"/!O49BY=V@LM?F;\]NWS@!BU- MUAF>!Z6U=19%;=N&[2Q4^N3RN%!/#[L#*YTOPJ4?.,-@9/DN_^(E\_D\ZJLC M]"]D]ZS%J#&+1CL.;GAF>KF=8OUPWT"#_R+\B8PPXE^1)"6S).Q,$;AI SS MT$K@'H\ _N''?CN)\IIW(5-5Y O16KFE="9[3JGQF <>0/P7B9.A[<^=-#.X6T=5^W/X&4$L#!!0 ( ,M#05BDZ"TR,#(T,#$S,5]D968N>&ULO55/:]LP%+\/]AW>O,,VF"P[ M66$-34O:[E!(QTBWT5M1Y)=83):")"?IMZ]D1UY"4V@&60[!]OO]>\^R=':Q MKB0LT5BAU3#)TRP!5%P70LV'26T)LUR(!*QCJF!2*QPFCVB3B_.W;\[>$7)_ M.1G#M>9UAI96#<<7 M\ZYR[?5 SX 'Y8::]6B6TU[6^]*![O3,K9A!8(:7PB%WM6$2"K1BKL 'A[:A M 8P^<+@NF:G8PF#%5&@*1DN7=EI7>O%HQ+QT\)%_@F #-^3[MY]P65NAT%JX MT[(.4>QGN%$\A9&4, D,"Q.T:)98;.2D4'\&X6_J^P,_:&4':RN&2>G<8D#I M:K5*5_U4F[GOQS=U?SN^XZ7/180* ^>81%90VV2/S@ M -K1&2UQ@C. 7I:WLN]W M0.YQX=>Q%=5"^D'0+4N_@J+K/NBVQPOMQ:F%ODX:Z])+&%Y/D13"?R;A"TA@ M8[3=5:2C<8NE?@V*D[*U+HBHD#(S]G'SUOXT,JK*;A11\4=I=Z[*1, MRL/R-81CIU+:C0X-%CG_<2WBC-72_?-BC/3MQ/ZA4"+L:F-_NY,:UPY5@47, M'>1>LPLYX0(P:W\YD+]G)($&"3_8'/T!,M/^, K>[<87,TG-=X+(L.]J\WQ^ M-C9ND:=SO:0%BG Z]L-%V +[[011/#2^HZEUAG$7E22;HFST'SQFT\1F.G3/ M>,*Y1G<.MO,G4$L#!!0 ( ,M#05A$NXDYK04 ,(S 5 :7!I>"TR M,#(T,#$S,5]L86(N>&ULS5MM;^HV%/X^:?_AC'W8)BVDT&E:4=LKRNV=T.B+ MH'>[VC1=I8D!:XF-;%/@W\_."Y#$3FAUKY,O;8B?Y_@Y/H].G 0NWVVC$%X0 MXYB2JTZO>]8!1'P:8+*XZJRYXW$?XPYPX9' "RE!5YT=XIUWU]]^<_F=XWRZ MF4[@/?77$2("1@QY @6PP6():NC.XP(QQTG1?R;S#*#?/>^>_;8_?^-QR:(D MYLC!WG[DO8P'= Z^BAQ3S_KN6<_MG_5_V8-F="XV'D/@,7^)!?+%FGDA!(CC M!0$I')*$!C#\P8?W2X]%WHJAR",J*1B^B.X^UHBN=@POE@)^]'\"-0V,G?O; M)[A9C(9HBN80BQZ(W4HZBN-H%2I)\;DE0W.]E) Q5_%=@A;*:&J:"S5- M[U*_ MZ/0SX3'QIB4O\RTG\$2%%[Y)^C'3LNA[]+;5/O!LK[+L^NAMJWS$_ JB15GP MJY=6MZ:A.C611SF!:"L0"5"0250!*CIN'#]N[''D?6SJYZ*&JG=35LZ;RZAQ M1([\[H*^N '"ZK)YK@X<=1"G+#]\'E&Y 1@^<\$\7V21XB2N.IIQ-R](X88L M4R4OP36)I0C7I_("MQ).>-P2YXQ&VDG3G*EF\'/XO.9J?@51*SNNLP+2A_A:RB"Q(H'+"@P UX820W['*7/)8M:?L'VAFS M*N%LNL$@,F^' J@U?M#K,A@B!4.,!@FW:HGL#NY)1M3DDQ^V8P"=I*SNQV,M M*+=&3K'*^UMDA;%:VJ&<-E!3?PB]A49\8=Q.<;6BLNKF!EM07IV>8GWW&%"@ M!MKY;838 I/%[XQNQ')$HY5'S$W=@+;9VBL%YQN\%MH"8]2K,S3[C ()!U)2 M(RU__PQ!/6JK:&X%G-V+@%9D\6J0 [7 'E6ZC->'! P2#0K>0"?Y@$-TOXZ> M$3-:_AABLV>4I>4;Q6&\!>4W2#*T!(6#!-A S":D\49T+3>D MNQ$-S/>)-2R;SC@I@;Q9*BFM\<\I*@V6RE$AYD)*!L5NP&=/WG8*7_BBS[37NE?ZI7^BWV2O\-7NDWYY61 M/'Q@3W1#ZG(\1C;@D[)0K4L.L+9YI*2LQB$*#P\,%*,Y?\3;J ?VR.@+)KYY M;VR"-^ 4@V2M70K8MGE&+Z_&.,G.5SHGHS7GGD?*A1?^C5>5]U5Z< /.TA,? M5UIB[-=6?=4N?%Q28G[$5H;8J;%)6E;GXG@+:FV05*QW#(,8U\1]ZU\,"X'( MB$;1FJ3WSUR3C0%GI_J5(C,+:$$M\$&5KJ(94BSDP58-,:,A]K' 9'$G=R8, M>[J<=" [5C#+RWQ01K3 !$9110<<@) AK9;_D2%E/B2+$']K0'TKD#W,Y]JK M0178CAWJY6:V,"-;8(]:<46;2 (<,R"A0,QITC!CSM>(OC@_;MOO[G^+@P_WHX>R)V,%RD(0_H*J(&$K)B9$WOHD6H#*@QWZK^V M\W1)N]%I--_NO[^E&J.DR&/P8&M_Y ['(W)*8CMR'MIL1\U6U&ZVW^Q%8SDU M*ZJ 4!7/F8'8+!3E) '-9H)@XF1KJ$MZ/\3D;DY52C,%*176%.DM36,_5E]F M&\5F;&9-TH6JU6C56G(=4,_:"ICX\/XWB.>85, M6. Q!$64':4LKG5U=17E1POIB7(]4;R8HQ,5Z:! 2F4I<;G;N+84B*R[CHT2X+8)\ MY=GFH3&1'+6&N#&3RR@!9M=_Q[ZQ0#HY#/SP*9^W-]%&T=@4(W$Z 9Z/_PDU MKR31?Y[3O4!4FQ',F)U3F">:0GEJY B@ GT&^\[0.U-KWL!D-03";W(K'W MJ?7;PBNI$^I?/.X/I=8\K.T/C,/3(IU\N?4J6]"'*B>TOWI;Q:>&/%#%SD6J M3*HR[:$<+W0]2- @F[)M*W9^Q5>& M.)7@K;<2G+'J 7XO21"2WKU@APBM.O"E;NIQMA=0-L(]NLM;; M12F/)6HP)88\,J:_VQK_ZU2S]-I MU1Y1IW>#[:,W/._2)_2!U@M07XN^),JM #[Z1%?')V6XCDZ\8+?SV?[_O3UB MG^Q_PN_^!5!+ P04 " #+0T%8+3_+\!D/ #4P "P &EP:7A?.&LN M:'1M[1QK=^*X]7M_AAA"9NDFD /,[G:_] A;@!ICNY*= M0']][Y5LL'DDS$Q(D^G,ATEL7=U[==]7LG+QM\7<)?=,2.Y[[W^R\N9/A'FV M[W!O^OZGUK#=[?[TM^:?+F8A@ &H)^M\\3XW"\.@7B@\/#SD%V/AYGTQ+11- MJU3@GLL]]ON'P75N!1[NAE^#%D)!/3GQQ9R&P 9BJAAFT2B>I9 8DMD91/"< MG_KW3^*I&24KP6-'0L#REBM$BIL$4S(*$XNE>$J&Y$-)<6Z=GY\7%BB2!.]" M\EV 1=.T"K_?7 _M&9M3@WLRI)[-5K. \;O]!' T =V"3(G=+!5P>$SE&C., M\D?@MSB!42?,2B4&KA3T8 :4[P0]TZ \ 748WRUH&$C+N.Y%\]W,.J$HA,N M%0"""6ZO)OC> 7-\S]B8)]ADKU3."C"Z,CCIEXM6]3$1:HAD0B0-X;ML;2\3 M*L<*.AG)K-CV(R\4^^Q0#V8F1*'8R\QY 4830"E" Y>_@Y/54 8SR&MCPFYQ MPAS3,"VC:*5([22295P:4TJ#G7+!@0PP#U+1!1_RMC]'B#($%RO7O)@QZC0O M0AZZK(GC_ZS=Y<$1+PKZU<6?#>/2MT'I7DC:@M&0.62\)!@=;J@,F3",YL6< MA90@$8/].^+W[W-MWPMAAC&"=>:(K9_>YT*V" O*S0O-BX(F/?:=)9'ATF5Z MW* NGWKU?T4RY)-E8P)SZY89A"3D"#&91L6+ZC;]1RV^(4M8X$LP@$ZSQ6P@?I 2RA9H;_^ M79/FBWNC6#%S31-B7ZE2@=\O"AEZ^\FW0&T.JN[*I=/#R>J CZ3#^M@'5Z/> MA+H8#-<,@>VH=UN\%+)B@1# , BI MWLU46$%S-!)3S2^DHZQF Z=ZE'XDU),*T_5XG8K;1]:9@#.EI.2)._@\X4P0 MQ2K;F2/;W5^R&MF9;$'("3?29X@9XCP$GRJN68KF;<>6['I[ %-1I+G MA$@A(XX$3^1Q+9I/P\N5#.:,RDA "-!!N YCR?1D*'G&^5NXAC,*:MA"%R]% M#7X6/J!_NX$3O!W$FX94-D=#7WSA*K;FX\M+YOES[NU">^AJ,B@*6>XSBRYD MK;>0"BX%F !QF8Y=EL0XC&&&Y/]A=2M8-!ZX$\X@I)D_@H1"C*+P R:&3@+_ MH3^X[ R,#_W1J']3)Y5@0:3OA_$C!/@9?W(8OQ'0*BJ_F1;"#-8BQ*MH: M$SKG[K*^.][6S6"1:_[U!^O,;.C_+PI!"N%5OS8.U#SJ]$1ET;ON#$;G]-!A^:L'SJ/_RCC<" M[])KMTJD/R!6Y>3RG7[1OR*CGSO_NUBPB@.M]H@ ,]9YJ?P-60-6)L2?D $+ M?!&2D^294F:Y.$_HRIB58%2X#]]<OU?6QBHR.W/K<%-J]WY-.JV6]=#TNVU\P?94B%T5J7= M/G$?0X@GG06U0X*KTKZ>K)-0288!L[$G<@CW2!NJ9YC];H/=O97E*W2*9$_A M8+^H58[K%YI*R?RQ<<]$R&WJQIR&?G!DI]D;=7%W&7O8D 7"OT='^+*PJQVG MZT',#^*P/T2L;;VEU_:=C!^5<\T>NZ<.W>$NFWZREK 68.7'9Q!6*F*F>YQ= M5-^.7K]4;5?<98!CS$1:1Q7<.8$)U5*E^EU-KT!-([KHQAM7MO*P;9V=Y9HE MTS K9Y6S"2X=;N-BTSI_2;MZL;6W M_?F<2SR/).B01&OWW3>_[NX FJMYX/I+)EZM94*UE$EN+ZZ68RSJ"%1>H8%E M8R;I^?GO5>VS5[7ERIM-JRW'$4S*^,S9L7CEDF_#KWTQ\A^\]$+/<\W?Z!V# MAM1U-A=ZNBGLHW4T,8NJ+NF+6\#(U>K<=^&/KSM^39MSZ8@_L'#S:ZT)H%'8Y5JVT?U+_^0CE>&N[BW HP M21Y0EW06S(Y"?L](?P+YCLGGK5(^R\!>3!*@5X**?0U)_6@TUCMU?_VA5K2J M#0E@+@MFOL>(IQJ%4P)FX$:8X@D5C(+7.*Q.#MZ8CTW^Y*M]#\-Y"QC8]+9B MKGE>K6WZVKNOSYO7/MC9+8IBJR&NE8!HT3+*5O&Q=CC>HGWK9SA'I*'J^ERS M/6/V'8'>G- TFL@./;K8W]!QLSU'PB?J,$K2,>D9OQ")MQ%>^02C#-D8&T. M"7TB^3QR0^HQ/Y+NDD@P1CE9JIGQ!'\,5'6][FN48KU7K:R64&^9C$U\%XCC M/$SY'%MH24XD8^0C\YB R-CU8&ZD]A%(*U_,:W;?U8\IJX.+_,$@ ILH%RNQ/:,A#R%_PT0.:%MV M2$ZL*FE?#4BQ9.8!<#/#/??9T9I_;9+TFR'4%;; MH%MO>H-M)*=NVF8KK\!FUQR2>43^S"3CF%?NFW>+HZ?FT*R0PX);5U.Z?:! M"6A M'!@3'4#EHH!<2.1EE:=X"65(W-X_(ZMZSEH, QO ]FJ>P,3NR,/,Z9. M6''5J<^ H%&C'@%K0RNEX*;?Z% M.KLC4>CLT<"Q0Z3>-TVH?U3$VYIV.CK6'H^.;U;LWF$[@QV>;+2YQ<>'.VI M*I[S9LR.FRZ?>Y-F,[L]?0I[E(T8VZ42KYT&XYE8B^LS"K!1Y_>1T>U==GHC M;ZQ$MX6UP?Y];1,=T]V?/NAFQ. M*GFS2"Y90$48"?5Y["47X#>^D.A^;2CQ*&0]?;(B9(-TW-BKTJ -T@H"GWNA M*MA@9'L>QE/F2;QVMB0M(= '$5KN L]__9'N,66:L<-R96^=T_?(YD?WI^0# M%?",?R/ GH5J1]_@#\C:N63!7W=4&Q"F@U2&/'S!]5"-/2:"V9YBRQD!0X-9F,O\JS>() M5ZOE32O^PJ^#MTJ^%2MO8?J%-*V/-< ,;->'E'V*.D_,OUA4YF^>9HQBPETP M JK3/_A_2.B4XA^K(.UH/H?,(LFM0&/ DOB47%^WL036IAP#)+:,I;DJH2-5 M5D#D\B,1)DD?&V#?>V#4!;.$=YE/%\A).]_*XQ=2P*)1K;9_-4W+M, ])&-W M0.244)@])7[<.R#=4W0/EPH=S\">.4-25'N&RZADVLJQ3MECYH%B-%@=9+/5 M0;:O#[)!WD)=U=6MQY!!D8]'?<"G52- 6_,#Q1M^^81_!@7\'G2@JRVDC,45 M#D.>1G\"(A/$CQ>-9)Y ?&I%4U D*9XK_92T?D*U"8IS=7>!BTE:Z_5*NG9Z8)6E5= M%I@J"WRH12'&N#!%97K&5%V*9XOX$Y;J17-UBB?P-I@^;I/X,"Q_C.HO@E M6Y__[W7F]GW2[L=>:_1IL/=2^RM9PZ$9[S;59.I""(*46)>S!^SEG&X>[V/S M[$00O&T:8<.K(J^^=XIDQN##NAZ$R,N!S)C-J#O!GAP1J=V]& "2 H/(Z&MT MD!EF4%W^ASDO&'3>[%;(_SQP9AP?XZCOXF@R@]"2$M47DJ9"(5YJ=.KEB8Z$3;W*-.3X6^K"L/_&]YV82 M ;QLWBS( KEF/NG,!+0:LXL"O#M<=,]_&O4<./&N:SV#,K/"^-WG2#^KR^8( M*[7ZQLOV#*O@S>\QQ7YZ1TQJW^N>KZE[2H>>C[V2S/UH)"_$O./?=FO^%U!+ M 0(4 Q0 ( ,M#05C+_]_VB 0 (,6 1 " 0 !I M<&EX+3(P,C0P,3,Q+GAS9%!+ 0(4 Q0 ( ,M#05AT_Z9YV0$ (L# 5 M " ;<$ !I<&EX+3(P,C0P,3,Q7V-A;"YX;6Q02P$"% ,4 M " #+0T%8I.G-QY$" !$" %0 @ '#!@ :7!I>"TR M,#(T,#$S,5]D968N>&UL4$L! A0#% @ RT-!6$2[B3FM!0 PC, !4 M ( !APD &EP:7@M,C R-# Q,S%?;&%B+GAM;%!+ 0(4 Q0 M ( ,M#05@L@Z_L2@0 &P@ 5 " 6%\X:RYH=&U02P4& 8 !@"$ 0 )B, # end XML 17 ipix_8k_htm.xml IDEA: XBRL DOCUMENT 0001355250 2024-01-31 2024-01-31 iso4217:USD shares iso4217:USD shares 0001355250 false 8-K 2024-01-31 INNOVATION PHARMACEUTICALS INC. NV 001-37357 30-0565645 301 Edgewater Place Suite 100 Wakefield MA 01880 978 921-4125 false false false false false